UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of Human Immunodeficiency Virus Type 1 Subtype C

ABSTRACT Entry of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by the virion surface envelope (Env) glycoproteins, making it a desirable target for antiretroviral entry inhibitors. We previously isolated a family of gp120 binding RNA aptamers and showed that they neutralized the infectivity of HIV-1. In this study, we assessed the activity of a shortened synthetic derivative of the B40 aptamer, called UCLA1, against a large panel of HIV-1 subtype C viruses. UCLA1 tightly bound to a consensus HIV-1 subtype C gp120 and neutralized isolates of the same subtype with 50% inhibitory concentrations (IC50s) in the nanomolar range. The aptamer had little toxicity in tests with cell lines and primary cells. Furthermore, it exhibited high therapeutic indices, suggesting that it may be effective at very low doses. Mapping of UCLA1 binding sites on gp120 revealed eight amino acid residues that modulated neutralization resistance. This included residues within the coreceptor binding site, at the base of the V3 loop, and in the bridging sheet within the conserved V1/V2 stem-loop of gp120. The aptamer was also shown to have synergistic effects with T20, a gp41 fusion inhibitor, and IgG1b12 (b12), an anti-CD4 binding site monoclonal antibody. These results suggest that UCLA1 may be suitable for development as a potent HIV-1 entry inhibitor.

[1]  J. Sodroski,et al.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. , 2000, AIDS research and human retroviruses.

[2]  L. Morris,et al.  Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals , 2009, Antimicrobial Agents and Chemotherapy.

[3]  D. Burton,et al.  An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. , 2008, Virology.

[4]  Antu K. Dey,et al.  An Aptamer That Neutralizes R5 Strains of Human Immunodeficiency Virus Type 1 Blocks gp120-CCR5 Interaction , 2005, Journal of Virology.

[5]  M. Goldsmith,et al.  Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.

[6]  Lynn Morris,et al.  The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.

[7]  H. Katinger,et al.  Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1 , 2005, Journal of Virology.

[8]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[9]  W. James,et al.  Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. , 2002, Biochemical and biophysical research communications.

[10]  Siamon Gordon,et al.  Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers , 2003, Journal of Virology.

[11]  John J Rossi,et al.  Cell-specific aptamer-mediated targeted drug delivery. , 2011, Oligonucleotides.

[12]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[13]  Paul W. H. I. Parren,et al.  Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.

[14]  D. Montefiori,et al.  Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.

[15]  E. Jenny-Avital.  Enfuvirtide, an HIV-1 fusion inhibitor. , 2003, The New England journal of medicine.

[16]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[17]  H. Katinger,et al.  Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies , 2001, Journal of Virology.

[18]  L. Morris,et al.  N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization , 2007, Journal of Virology.

[19]  Peter D. Kwong,et al.  Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.

[20]  Z. Weng,et al.  Ancestral and consensus envelope immunogens for HIV-1 subtype C. , 2006, Virology.

[21]  David D. Smith,et al.  Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. , 2011, Methods.

[22]  S. Karim,et al.  Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. , 2010, Virology.

[23]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[24]  S. Tope,et al.  Aptamers as therapeutics , 2013 .

[25]  C. Broder,et al.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.

[26]  Q. Sattentau,et al.  International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II , 2009, PloS one.

[27]  D. Thompson,et al.  Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. , 2001, The Journal of infectious diseases.

[28]  Wei Wang,et al.  Progress in Aptamer Screening Methods , 2009 .

[29]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[30]  John J. Rossi,et al.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells , 2009, Nucleic acids research.

[31]  Feng Gao,et al.  Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.

[32]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[33]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[34]  L. Morris,et al.  Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site , 2011, Journal of Virology.

[35]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[36]  C. Williamson,et al.  A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. , 1999, AIDS research and human retroviruses.

[37]  Lynn Morris,et al.  Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B , 2006, PLoS medicine.

[38]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[39]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[41]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[42]  A. Trkola,et al.  Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. , 2000, The Journal of infectious diseases.

[43]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[44]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[45]  D. Schols.  HIV co-receptor inhibitors as novel class of anti-HIV drugs. , 2006, Antiviral research.

[46]  Susan M Lea,et al.  Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. , 2005, RNA.

[47]  M. Joubert,et al.  A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization. , 2010, Biochemistry.

[48]  Hui Li,et al.  Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[49]  Mark Connors,et al.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.

[50]  E. Neuwelt,et al.  Combined intraarterial carboplatin, intraarterial etoposide phosphate, and IV Cytoxan chemotherapy for progressive optic-hypothalamic gliomas in young children. , 2001, AJNR. American journal of neuroradiology.

[51]  Ross D. Cranston,et al.  Protection of HIV Neutralizing Aptamers against Rectal and Vaginal Nucleases , 2010, The Journal of Biological Chemistry.

[52]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[53]  Lynn Morris,et al.  Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.

[54]  Martin S. Hirsch,et al.  Strong in Vitro Synergy Between the Fusion Inhibitor T‐20 and the CXCR4 Blocker AMD‐3100 , 2000, Journal of acquired immune deficiency syndromes.

[55]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[56]  William C. Olson,et al.  Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes , 2001, Journal of Virology.

[57]  C. O’Sullivan.  Aptasensors – the future of biosensing? , 2002, Analytical and bioanalytical chemistry.

[58]  R. Doms,et al.  The entry of entry inhibitors: A fusion of science and medicine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Zolla-Pazner,et al.  The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates , 2005, Journal of Virology.

[60]  Q. Sattentau,et al.  International Network for Comparison of HIV Neutralization Assays: The NeutNet Report , 2009, PloS one.